Alto Neuroscience (ANRO) Current Assets (2023 - 2026)
Alto Neuroscience (ANRO) posted Current Assets of $269.1 million for Q1 2026, up 51.43% sequentially from $177.7 million in Q4 2025, and up 64.58% YoY from $163.5 million in Q1 2025.
Alto Neuroscience (ANRO) Current Assets (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Current Assets for 4 years, with the latest figure at $269.1 million in Q1 2026.
- Quarterly Current Assets rose 64.58% year-over-year to $269.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $269.1 million (up 64.58% YoY) and the FY2025 annual result came in at $177.7 million, up 4.95% from the prior year.
- Current Assets improved to $269.1 million in Q1 2026 per ANRO's latest filing, from $177.7 million in the prior quarter.
- Over five years, Current Assets peaked at $269.1 million in Q1 2026 and troughed at $85.4 million in Q4 2023.
- A 4-year average of $174.2 million and a median of $173.5 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets jumped 98.31% in 2024, then decreased 24.02% in 2025.
- Over 4 years, Current Assets stood at $85.4 million in 2023, then surged by 98.31% to $169.3 million in 2024, then increased by 4.95% to $177.7 million in 2025, then jumped by 51.43% to $269.1 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $269.1 million, $177.7 million, and $139.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 247.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 247.32 Mn |
| Mar 31, 2026 | 269.13 Mn |
| Dec 31, 2025 | 177.72 Mn |
| Sep 30, 2025 | 139.45 Mn |
| Jun 30, 2025 | 149.85 Mn |
| Mar 31, 2025 | 163.52 Mn |
| Dec 31, 2024 | 169.34 Mn |
| Sep 30, 2024 | 183.53 Mn |
| Jun 30, 2024 | 195.41 Mn |
| Mar 31, 2024 | 208.31 Mn |
| Dec 31, 2023 | 85.39 Mn |